Transdermal Drug Delivery Systems (TDDS) Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type (Patches, Gels and Ointments), By Application (Neurologic Conditions, Pain Management, Nicotine Cessation, Cardiovascular, Others), By End-User (Hospitals and Clinics, Surgical Centers, Home Care Settings), And By Geography - Forecasts From 2022 To 2027

The transdermal drug delivery system (TDDS) market was valued at US$5.668 billion in 2020 and is expected to grow at a CAGR of 4.89% over the forecast period to reach a total market size of US$7.917 billion by 2027.

A transdermal drug delivery system (TDDS) is a type of controlled drug delivery system in which medicines are administered via the skin at a predefined and regulated pace. These systems are used to treat a variety of diseases, including cardiovascular and central nervous system disorders. Scopolamine (for motion sickness), nicotine (for quitting smoking), nitro-glycerine (for angina), and lidocaine (for shingles pain) are drugs that can be administered through skin patches. These devices provide a number of advantages, including a prolonged therapeutic effect, fewer side effects, greater bioavailability, enhanced patient compliance, and the capacity to easily discontinue medication therapy. The appendageal, transcellular, and intercellular pathways are the three major routes of drug entry. The growing geriatric population, as well as the increase in chronic conditions such as orthopedic diseases and other disorders among the elderly, is driving up demand for transdermal drug delivery patches.

Furthermore, transdermal drug delivery systems have numerous advantages, such as improved safety, effectiveness, and reduced inter-patient variability of dosages. The increased demand for self-administration of medicines for diseases requiring long-term therapy, such as diabetes, is boosting this industry. In the event of diabetes, insulin must be continuously delivered into the patient's body via injections. The use of insulin injections on a regular basis causes discomfort and increases the chance of infection transmission. The growing patient preference for pain-free medication administration has resulted in a considerable increase in the adoption rate of drug-administering adhesive skin patches, which is expected to offer the market strong growth potential. Furthermore, the inclusion of transdermal systems will improve patient self-reliance by significantly reducing the frequency of hospital visits and cumulative treatment expenses.

North America has the largest market share in the transdermal drug delivery market. The market is expecting favorable growth due to the COVID-19 pandemic. This is mostly attributed to the development of unique treatments. For instance, the United States Food and Drug Administration authorized “T3X,” an over-the-counter ointment formulated by Advanced Penetration Technology, in August 2020. It is authorized for use against the SARS-CoV-2 virus. within 30 seconds, T3X was effectively able to eradicate the virus. According to GLOBOCAN statistics, about 105,000 new cases of melanoma skin cancer were recorded in the North American region in 2020, with a projected increase to 142,000 by 2040. The rising prevalence of skin-related diseases is projected to fuel market expansion. Furthermore, increased product releases are projected to drive market growth in this area.

Growth Factors:

• Globally, the prevalence of chronic diseases is increasing, as is the demand for therapeutics.

The market for transdermal drug delivery systems is expanding due to increased chronic disease prevalence, rising healthcare costs, and a growing geriatric population. Furthermore, this market is being fueled by a high demand for self-administration of medications for diseases that require long-term therapy, such as diabetes. Insulin must be administered into the patient's body on a regular basis in order for diabetes to be controlled. As a result, the need for automated medication delivery systems has increased in recent years. Several unique medications that can be administered by transdermal drug delivery have been introduced. This positive market activity is likely to fuel the market expansion. Furthermore, the growing preference of patients and physicians for pain-free medicine administration, which is projected to drive market demand throughout the forecast period, is a significant contributor to market growth. These variables are anticipated to enhance growth prospects throughout the forecasted period.

Restraints:

• Transdermal drug delivery systems are expensive:

The high cost of transdermal drug delivery systems such as radiofrequency, electroporation, and others is likely to limit the transdermal drug delivery system market growth. The high cost of the transdermal drug delivery system adds to the public’s distrust. Furthermore, issues with various delivery systems, such as pain and edema at the application site, are likely to pose a market challenge.

COVID-19's Impact on the Transdermal Drug Delivery Systems (TDDS) Market:

Since the beginning of COVID-19, the global market for transdermal drug delivery systems has grown at a rapid pace. Transdermal drug delivery is critical in promoting quality healthcare because coronavirus cases have increased in almost every country. For instance, the United States Food and Drug Administration (US FDA) approved Winlevi (clascoterone cream 1%) formulated by Cassiopea SpA for the treatment of acne in August 2020. However, the major market participants are working hard to return the shares to normalcy in the midst of COVID-19.

Competitive insight:

• In September 2021, Luye Pharma Switzerland AG, a wholly-owned subsidiary of the Luye Pharma Group, and Esteve Pharmaceuticals, S.A. announced their agreement in which ESTEVE would have exclusive rights to market the Rivastigmine Multi-Day Transdermal Patch developed by Luye Pharma in Spain.
• In July 2021, ACG, one of the world's most integrated pharmaceutical suppliers, established a strategic alliance with Danapak Flexibles A/S, the global market leader in packaging for high-barrier transdermal drug delivery systems. The collaboration would result in improved services for Danapak Flexibles' existing and future clients in India.

Market Segmentation:

• By Type
  • Patches
  • Gels & Ointments
• By Application
  • Neurologic Conditions
  • Pain Management
  • Nicotine Cessation
  • Cardiovascular
  • Others
• By End-User
  • Hospitals & Clinics
  • Surgical Centers
  • Home Care Settings
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • UK
    • France
    • Germany
    • Italy
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • Thailand
    • Taiwan
    • Indonesia
    • Others

---

1. Introduction
1.1. Market Overview
1.2. COVID-19 Scenario
1.3. Market Definition
1.4. Market Segmentation

2. Research Methodology
2.1. Research Data
2.2. Assumptions

3. Executive Summary
3.1. Research Highlights

4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Force Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5.  Transdermal Drug Delivery Systems Market Analysis, By Type
5.1.  Introduction
5.2.  Patches
5.3. Gels & Ointments

6. Transdermal Drug Delivery Systems Market Analysis, By Application
6.1.  Introduction
6.2.  Neurologic Conditions
6.3.  Pain Management
6.4. Nicotine Cessation
6.5.  Cardiovascular
6.6.  Others

7. Transdermal Drug Delivery Systems Market Analysis, By End-User
7.1.  Introduction
7.2.  Hospitals & Clinics
7.3.  Surgical Centers
7.4. Home Care Settings

8. Transdermal Drug Delivery Systems Market Analysis, By Geography 
8.1.  Introduction
8.2. North America
8.2.1.  United States
8.2.2.  Canada
8.2.3.  Mexico
8.3.  South America
8.3.1.  Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1.  UK
8.4.2.  France
8.4.3.  Germany
8.4.4. Italy
8.4.5.  Others
8.5.  Middle East and Africa
8.5.1.  Saudi Arabia
8.5.2.  UAE
8.5.3.  Others
8.6.  Asia Pacific
8.6.1.  Japan
8.6.2.  China
8.6.3.  India
8.6.4.  Thailand
8.6.5.  Taiwan
8.6.6.  Indonesia
8.6.7.  Others

9.  Competitive Environment and Analysis
9.1.  Major Players and Strategy Analysis
9.2.   Emerging Players and Market Lucrativeness
9.3.   Mergers, Acquisitions, Agreements, and Collaborations
9.4.   Vendor Competitiveness Matrix

10.  Company Profiles
10.1.  3M
10.2.  Zosano Pharma Corporation
10.3.  Medherant Ltd.
10.4.  Tapemark
10.5.  Toyochem Co. Ltd.
10.6.  Haemonetics Corporation
10.7.  AdhexPharma
10.8. Boehringer Ingelheim GmbH
10.9. Sparsha Pharma International Pvt Ltd.

3M

Zosano Pharma Corporation

Medherant Ltd.

Tapemark

Toyochem Co. Ltd.

Haemonetics Corporation

AdhexPharma

Boehringer Ingelheim GmbH

Sparsha Pharma International Pvt Ltd.